Skip to main content

Table 1 Clinical data on the patients at the time of biopsies

From: Effects on muscle tissue remodeling and lipid metabolism in muscle tissue from adult patients with polymyositis or dermatomyositis treated with immunosuppressive agents

Patient ID

Diagnosis

Age (years)

Gender

Disease duration (months)

Cumulative cortisone (mg)

Imuunosuppressive treatment at second biopsy

Autoantibodies

Support for diagnosis

MMT-8 (%)

s-CK (μcat/L)

HAQ (0.0–3.0)

FI-2 (%)

B

A

B

A

B

A

B

A

1

DM

40

M

3

14450.0

Pred, AZA

MDA5, SSA, Ro60

MW, S, LD

87.5

87.5

1.3

1.1

1.13

0.75

21.7

27.4

2

PM

73

F

12

6222.5

Pred, MTX

Neg

MW, CK, MB

85.0

85.0

10.2

1.5

0.5

0.88

18.3

19.1

3

DM

69

F

2

10017.5

Pred, MTX

ANA, TIF1γ

MW, CK, S, EMG

81.4

91.3

29.3

1.0

0.63

0

0

11.2

4

DM

63

M

0.5

7330.0

Pred, AZA

Neg

MW, CK, S, EMG

78.8

90.0

48.2

1.0

0,38

0

86.2

100.0

5

DM

45

F

16

6842.5

Pred, MTX

ANA, Mi-2

MW, CK, MB, S, EMG

98.8

87.5

43.0

2.1

1.5

0.88

17.3

25.3

6

PM

71

F

12

8415.0

Pred, AZA

Neg

MW, CK, MB

75.7

100

9.0

3.9

1.25

1.88

NA

17

  1. A after treatment, ANA antinuclear antibodies, AZA azathioprine, B before treatment, CK creatine kinase (reference interval, male: 3.3 μkat/L, female: 2.5 μkat/L), DM dermatomyositis, EMG positive for electromyography, F female, FI-2 Functional Index-2 (0–100 %; impairment in performing repetitions, respective no impairment), HAQ Health Assessment Questionnaire (0.00–3.00; no impairment, respective impairment), LD lactate dehydrogenase (reference interval 105–333 IU/L), M male, MB positive muscle biopsy, MDA5 melanoma differentiation-associated protein 5, MMT-8 manual muscle testing in 8 muscle groups (0–100 %; muscle strength), MTX methotrexate, MW muscle weakness, NA not available, PM polymyositis, Pred prednisone, S skin rash, s-CK serum creatine kinase, SSA anti-Sjögren’s syndrome-related antigen A (also called anti-Ro), TIF1γ transcription intermediary factor 1-gamma